Mirasol Evaluation of Reduction in Infections Trial

Inclusion Criteria: * Willing to participate in study and patient or legally authorized representative has given written informed consent (IC) * Hemoglobin \< 7 g/dL or decision to transfusion by clinical team * Transfusion necessary based on clinical judgment of attending physician * Agree to return to the hospital for the follow-up visits Exclusion Criteria: * Presence of red cell alloantibodies * Incompatible red cell crossmatch * Not expected to survive for 10 weeks * Expected to require plasma or platelets within next 10 weeks outside of the FWB provided in the trial * Blood type AB (due to concern of limited supply) * Weight \< 30 kg (due to concern for sufficient blood draws to detect bacteria and other TTIs) * HIV-infected * Clinical suspicion of sepsis * Anti-malarial treatment within 7 days prior to randomization * Fever (central body temperature greater than 38.5°C) * Transfusion(s) of a blood product within 1 month prior to randomization * Acute or chronic medical disorder that, in the opinion of the investigator, would impair the ability of the patient to receive protocol treatment